Mode
Text Size
Log in / Sign up

Postoperative VTE prediction models show substantial heterogeneity and high bias risk in lung cancer surgery patients undergoing systematic review analysisExisting lung cancer VTE prediction models show mixed results in surgery patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Existing postoperative VTE prediction models for lung cancer patients lack sufficient evidence for routine clinical use due to high bias and heterogeneity.

This systematic review and meta-analysis evaluated the predictive performance of twenty models designed to assess postoperative venous thromboembolism risk in patients with lung cancer. The pooled analysis yielded an area under the curve of 0.85, with a 95% confidence interval ranging from 0.78 to 0.93. However, this aggregate metric obscures considerable inconsistency across the eight validated models included in the evaluation.

Substantial heterogeneity characterized the results, with an I-squared statistic of 89.1%. Reported discrimination capabilities varied significantly, spanning an AUC range from 0.66 to 0.99. This wide dispersion suggests that model performance is not uniform across different clinical settings or patient subgroups.

Critical limitations further constrain the applicability of these tools. The majority of studies were retrospective and single-center, contributing to a high risk of bias according to PROBAST standards. Few studies employed machine learning methods, and the extant evidence does not support the routine clinical use of existing postoperative VTE prediction models in this specific population.

Doctors need reliable ways to spot patients at risk for blood clots after surgery. Lung cancer patients face a higher danger of these clots, known as venous thromboembolism. A recent look at twenty different prediction models tried to measure how well these tools work. The combined results showed an average accuracy score of 0.85. However, the range of scores was huge, going from 0.66 to 0.99. This means some models work well while others do not.

The review found that most of the studies used were done in single centers and looked back at past data. These design choices create a high risk of bias. Because of this, the tools cannot be trusted to guide care for every patient. The differences between the models were so large that they cannot be used together in a standard way.

Safety issues were not reported in the review. The main problem is that the evidence is too weak to support using these models in daily practice. Doctors should not rely on existing tools for lung cancer patients undergoing surgery until better data is available.

What this means for you:
Current prediction models for blood clots in lung cancer surgery patients cannot be used routinely due to high risk of bias.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
BackgroundRisk prediction models for venous thromboembolism (VTE) in lung cancer patients undergoing surgery have increased substantially in recent years. However, the methodological quality, predictive performance, and clinical applicability of these models have yet to be systematically assessed.ObjectiveThis study aimed to systematically evaluate the published literature on the development and validation of postoperative VTE risk prediction models for patients with lung cancer.DesignA systematic review and meta-analysis of observational studies was conducted.MethodsA comprehensive search of CNKI, Wanfang, VIP, PubMed, Web of Science, The Cochrane Library, CINAHL, and Embase was conducted from inception to November 22, 2025. The data extracted from the included studies encompassed a range of characteristics, including design elements, predictors, model development strategies, validation approaches, and performance metrics. The Prediction Model Risk of Bias Assessment Tool (PROBAST) was utilized to evaluate the risk of bias and applicability. A meta-analysis of area under the receiver operating characteristic curve (AUC) values from validated models was performed using random-effects methods.ResultsA total of 4,700 records were identified, and after screening, twenty studies involving twenty prediction models were included. The majority of the studies were retrospective and single-center, and all were adjudged to have a high risk of bias according to PROBAST. Logistic regression emerged as the predominant modeling approach, while a limited number of studies adopted machine learning methods, including XGBoost and stacked models. The most frequently utilized predictors were D-dimer and age. The extent of reported model discrimination exhibited significant variability, with AUC values ranging from 0.66 to 0.99. A total of eight models that had undergone validation were deemed eligible for the quantitative synthesis, resulting in a pooled AUC of 0.85 (95% confidence interval [CI]: 0.78–0.93). However, substantial heterogeneity was observed (I² = 89.1%).ConclusionWhile several models showed some discriminatory ability, all included studies demonstrated a high risk of bias and limitations in applicability. The extant evidence does not support the routine clinical use of existing postoperative VTE prediction models in lung cancer patients. Future studies should adopt rigorous methodological frameworks, ensure adequate sample sizes, apply standardized predictor handling, and conduct multicenter external validation to improve the reliability and clinical utility of prediction models.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD420251232098.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.